Ophirex is developing affordable, accessible, oral treatments to snakebite.
Ophirex has raised $37.0M in total funding. The most recent round was Series B. The last funding was announced in January 2023.
Ophirex's investors include AXA Investment Managers.
Ophirex is headquartered in Corte Madera, United States.
Ophirex is developing affordable, accessible, oral treatments to snakebite.
Ophirex is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Ophirex — Funding & Investors." VCBacked, January 5, 2023, https://www.vcbacked.co/company/ophirex. Accessed October 4, 2026.
VCBacked. (2023). Ophirex — Funding & Investors. Retrieved October 4, 2026, from https://www.vcbacked.co/company/ophirex
{{cite web |title=Ophirex — Funding & Investors |url=https://www.vcbacked.co/company/ophirex |website=VCBacked |access-date=October 4, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated